Management of Resistant Hypertension

Definition and Diagnosis

Resistant hypertension is defined as blood pressure that remains above target (>130/80 mmHg) despite concurrent use of at least three antihypertensive agents, including a long-acting calcium channel blocker, a blocker of the renin-angiotensin system, and a diuretic at maximal or maximally tolerated doses, according to the European Heart Journal and Hypertension guidelines 1, 2
True treatment resistance should be confirmed by performing 24-hour ambulatory BP monitoring to exclude white-coat effect, as recommended by the Hypertension guideline 2
Medication adherence should be assessed, as poor adherence accounts for approximately 50% of apparent treatment resistance, according to the American Journal of Kidney Diseases and Hypertension guidelines 3, 2

The European Heart Journal recommends optimizing current regimen and lifestyle modifications, including sodium restriction (<2400 mg/day) and maximizing lifestyle interventions (weight loss, exercise, dietary modifications) 1, 2
The Hypertension guideline suggests substituting an optimally dosed thiazide-like diuretic for the prior diuretic, and adding low-dose spironolactone to existing treatment as the most effective fourth-line agent 2, 1, 4
If spironolactone is not tolerated, the European Heart Journal recommends using eplerenone instead, or adding further diuretic therapy, beta-blocker, or alpha-blocker 1, 4, 2

For severe hypertension requiring immediate intervention, the European Heart Journal recommends IV labetalol, oral methyldopa, or nifedipine as first-line agents, and IV hydralazine as a second-line option 1, 5
In acute intracerebral hemorrhage with SBP ≥220 mmHg, careful acute BP lowering with IV therapy to <180 mmHg should be considered, according to the European Heart Journal guideline 1, 5

The European Heart Journal and Hypertension guidelines recommend that initial antihypertensive treatment in Black patients should include a diuretic or a calcium channel blocker, either alone or with a renin-angiotensin system blocker 1, 6
For patients with heart failure, the European Heart Journal recommends treatment with ACE inhibitor/ARB, beta-blocker, diuretic, and/or mineralocorticoid receptor antagonist 1, 4
For patients with chronic kidney disease, the European Heart Journal guideline suggests targeting SBP 120-129 mmHg if eGFR >30 mL/min/1.73m² 4, 5

Pseudo-resistance is common and must be excluded before diagnosing true resistant hypertension, according to the American Journal of Kidney Diseases and Hypertension guidelines 3, 2
High sodium intake significantly contributes to treatment resistance, as stated in the European Heart Journal and Hypertension guidelines 1, 2
Medications like NSAIDs, certain antidepressants, and stimulants can interfere with BP control, according to the Hypertension guideline 2

Implement dietary salt restriction to less than 2400 mg/day, encourage weight loss, which can lead to significant blood pressure reductions, and recommend moderate alcohol intake, as suggested by the American Heart Association, with a strength of evidence based on observational studies and clinical trials 7
Consider supervised multidisciplinary lifestyle intervention programs, which have shown significant reductions in both systolic and diastolic blood pressure, although the specific guideline society is not mentioned in this context, the approach is supported by evidence from studies 7
Simplify medication regimen to improve adherence, using long-acting combination products when possible, as recommended by hypertension management guidelines, with a focus on improving patient outcomes 7
Volume overload due to insufficient diuretic therapy is a common cause of treatment failure, highlighting the importance of optimal diuretic use in resistant hypertension management, as noted in the European Heart Journal 8
Consider multidisciplinary treatment approach including nurse case managers, pharmacists, and nutritionists to improve outcomes, as this comprehensive approach can enhance patient care and adherence to treatment plans, with evidence supporting its effectiveness 7